Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Patients with higher BMI may need a higher dose to achieve the desired skin brightness
However, the participants in the STEP study were severely overweight with an average BMI of 37~38kg/, and the clinical trial was conducted according to overall Western obesity standards
Abstract Tirzepatide, a dual agonist for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has shown robust efficacy in treating diabetes and obesity, and in obese patients with heart failure with preserved ejection fraction (HFpEF), it reduced weight, lowered blood pressure, and improved outcomes
(2025) 8:e2453770
Book a consultation with Rewind Anti-Aging to discuss which treatment approach is right for you
However, this was largely dominated by tirzepatideanother weight-loss and diabetes drug from the American innovator Eli Lilly
US$ 29.30
US$ 28.91
US$ 24.74
US$ 21.81
